PARS2 and Miyoshi myopathy: Having identified ProRS as a possible anti-proliferative target in MM, we further evaluated three ProRS inhibitor chemotypes (Fig. 2A): HFG, ProSA (which is a high-affinity, non-hydrolysable prolyl-adenylate analogue) and NCP26 [16], which we developed based on T-3767758 (NCP22) [18].